Institute of Immunology and Genetics in Kaiserslautern selects Congenica to accelerate its whole exome sequencing
Congenica, the digital health company enabling rapid and accurate analysis of complex genomic data to transform people’s lives, today announces a new contract with the Institute of Immunology and Genetics (‘IIG’ or the ‘Institute’) a leading molecular genetic laboratory in Kaiserslautern, Germany, equipped with state-of-the-art equipment and comprehensive human genetic and bioinformatic expertise.
From analysis of established gene variants, through next generation sequencing (NGS) panel analysis of disease genes, to whole exome analysis of the entire genome, the IIG provides a full range of molecular genetic diagnostics with particular focus on diagnostics for hereditary diseases and anomalies during pregnancy.
The Congenica clinical decision support platform will be used by IIG to evaluate gene panels and whole exomes with greater precision and speed, enabling the Institute’s critical work in prenatal diagnostics to provide accurate life-changing answers with greater efficiency to more patients in Germany.
Dr Anne-Karin Kahlert, Institute of Immunology and Genetics in Kaiserslautern, said:
Congenica’s technology stands out as delivering rapid and highly accurate interpretation of genetic variants, enabling a genetic diagnosis in a very short time for targeted and therapy-relevant questions. This is of paramount importance to us in genetic diagnostics, especially for prenatal cases, which are a particular area of focus for us. The Congenica platform will allow us to dramatically reduce turnaround times in the diagnostic process, which will be of great benefit to our patients.
Freddie Sharkey, PhD, VP of Sales EMEA, Congenica, said: “This partnership with the Kaiserslautern Institute of Immunology and Genetics enables us to extend our foothold in the strategically important region and its surrounding territories. We look forward to supporting the Institute with their whole exome sequencing service, using our proprietary market leading genomic analysis technology.”